| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 15 | 2024 | 188 | 2.570 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 7 | 2025 | 53 | 1.870 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 7 | 2024 | 30 | 1.600 |
Why?
|
| Encephalitis | 7 | 2024 | 110 | 1.300 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 5 | 2017 | 14 | 1.200 |
Why?
|
| Brain Diseases | 4 | 2022 | 301 | 1.160 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 3 | 2012 | 23 | 1.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 6 | 2022 | 174 | 1.010 |
Why?
|
| Immunotherapy | 7 | 2025 | 665 | 1.000 |
Why?
|
| Rheumatology | 8 | 2024 | 119 | 0.930 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2010 | 26 | 0.900 |
Why?
|
| Status Epilepticus | 5 | 2025 | 144 | 0.860 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 145 | 0.840 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 105 | 0.810 |
Why?
|
| Psychotic Disorders | 3 | 2017 | 136 | 0.780 |
Why?
|
| Child | 54 | 2025 | 24453 | 0.780 |
Why?
|
| Autoantibodies | 7 | 2024 | 436 | 0.770 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2021 | 49 | 0.760 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 12 | 0.750 |
Why?
|
| Hashimoto Disease | 3 | 2024 | 21 | 0.710 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2024 | 143 | 0.710 |
Why?
|
| Plasma Exchange | 2 | 2018 | 84 | 0.650 |
Why?
|
| Brain | 9 | 2023 | 3009 | 0.640 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 251 | 0.630 |
Why?
|
| Pneumonia | 1 | 2022 | 326 | 0.610 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 252 | 0.600 |
Why?
|
| Seizures, Febrile | 3 | 2025 | 23 | 0.590 |
Why?
|
| Cytokines | 1 | 2023 | 1292 | 0.550 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 52 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 3586 | 0.530 |
Why?
|
| Central Nervous System | 2 | 2021 | 253 | 0.530 |
Why?
|
| Cognition Disorders | 5 | 2017 | 554 | 0.520 |
Why?
|
| Autoimmune Diseases of the Nervous System | 4 | 2021 | 33 | 0.510 |
Why?
|
| Dexamethasone | 3 | 2025 | 275 | 0.470 |
Why?
|
| Humans | 71 | 2025 | 124777 | 0.470 |
Why?
|
| Adolescent | 32 | 2024 | 19326 | 0.460 |
Why?
|
| Epilepsy | 2 | 2021 | 873 | 0.440 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2025 | 208 | 0.430 |
Why?
|
| Cerebrum | 2 | 2010 | 33 | 0.430 |
Why?
|
| Stroke | 4 | 2011 | 986 | 0.430 |
Why?
|
| Polyarteritis Nodosa | 1 | 2012 | 7 | 0.410 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 926 | 0.410 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 578 | 0.400 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2012 | 12 | 0.390 |
Why?
|
| Brain Edema | 1 | 2012 | 69 | 0.380 |
Why?
|
| Glucocorticoids | 5 | 2023 | 384 | 0.380 |
Why?
|
| Cerebral Ventricles | 1 | 2012 | 81 | 0.380 |
Why?
|
| Streptococcal Infections | 2 | 2024 | 244 | 0.370 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 376 | 0.360 |
Why?
|
| Quinolones | 1 | 2011 | 54 | 0.360 |
Why?
|
| Pediatrics | 5 | 2024 | 1155 | 0.360 |
Why?
|
| Immunosuppressive Agents | 6 | 2017 | 645 | 0.350 |
Why?
|
| ADAM Proteins | 1 | 2011 | 78 | 0.350 |
Why?
|
| Cerebral Hemorrhage | 1 | 2012 | 143 | 0.350 |
Why?
|
| Epileptic Syndromes | 2 | 2021 | 30 | 0.350 |
Why?
|
| Lupus Nephritis | 3 | 2017 | 44 | 0.350 |
Why?
|
| Antibodies, Antiphospholipid | 4 | 2011 | 19 | 0.340 |
Why?
|
| Female | 40 | 2024 | 66533 | 0.340 |
Why?
|
| Granulomatosis with Polyangiitis | 4 | 2016 | 38 | 0.330 |
Why?
|
| Male | 37 | 2025 | 61266 | 0.330 |
Why?
|
| Cerebellum | 2 | 2010 | 416 | 0.330 |
Why?
|
| Mentoring | 2 | 2024 | 75 | 0.330 |
Why?
|
| Immunologic Factors | 3 | 2021 | 174 | 0.320 |
Why?
|
| Rituximab | 5 | 2024 | 156 | 0.320 |
Why?
|
| Piperazines | 1 | 2011 | 238 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 265 | 0.320 |
Why?
|
| Anticoagulants | 3 | 2010 | 590 | 0.320 |
Why?
|
| Electroencephalography | 3 | 2024 | 869 | 0.310 |
Why?
|
| Program Evaluation | 2 | 2024 | 447 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 307 | 0.300 |
Why?
|
| Neutropenia | 2 | 2021 | 200 | 0.300 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.290 |
Why?
|
| Pneumonia, Viral | 2 | 2022 | 375 | 0.270 |
Why?
|
| Microscopic Polyangiitis | 3 | 2016 | 13 | 0.260 |
Why?
|
| Inflammation | 4 | 2023 | 1428 | 0.250 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 182 | 0.240 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2024 | 793 | 0.240 |
Why?
|
| Thrombosis | 1 | 2010 | 521 | 0.240 |
Why?
|
| Quality Improvement | 2 | 2024 | 638 | 0.240 |
Why?
|
| Mental Health Services | 2 | 2019 | 256 | 0.230 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 530 | 0.220 |
Why?
|
| Retrospective Studies | 14 | 2024 | 16298 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 502 | 0.220 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 29 | 0.210 |
Why?
|
| Child, Preschool | 15 | 2025 | 14050 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2016 | 465 | 0.210 |
Why?
|
| Cohort Studies | 10 | 2021 | 4783 | 0.210 |
Why?
|
| Chorea | 1 | 2023 | 39 | 0.210 |
Why?
|
| Lung Diseases | 2 | 2016 | 384 | 0.200 |
Why?
|
| Adult | 12 | 2024 | 29457 | 0.180 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.180 |
Why?
|
| Prednisolone | 1 | 2021 | 74 | 0.180 |
Why?
|
| Depression | 1 | 2009 | 1244 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2021 | 91 | 0.180 |
Why?
|
| Platelet Count | 1 | 2021 | 136 | 0.180 |
Why?
|
| Remission Induction | 2 | 2012 | 301 | 0.180 |
Why?
|
| Mentors | 3 | 2024 | 143 | 0.180 |
Why?
|
| Europe | 3 | 2017 | 354 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2022 | 224 | 0.180 |
Why?
|
| Nephrotic Syndrome | 2 | 2021 | 47 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 339 | 0.170 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 1894 | 0.170 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 33 | 0.170 |
Why?
|
| Parents | 2 | 2024 | 1029 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2021 | 80 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2021 | 316 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 226 | 0.160 |
Why?
|
| Social Workers | 1 | 2019 | 6 | 0.160 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2019 | 9 | 0.160 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 18 | 0.160 |
Why?
|
| Psychology | 1 | 2019 | 58 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2015 | 519 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 2 | 2010 | 55 | 0.160 |
Why?
|
| United States | 9 | 2024 | 10883 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 107 | 0.160 |
Why?
|
| Infant | 8 | 2021 | 12483 | 0.160 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.160 |
Why?
|
| Arthralgia | 1 | 2018 | 54 | 0.150 |
Why?
|
| West Nile Fever | 1 | 2020 | 139 | 0.150 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 3725 | 0.150 |
Why?
|
| Canada | 4 | 2024 | 299 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2023 | 149 | 0.140 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2017 | 12 | 0.140 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2017 | 59 | 0.140 |
Why?
|
| Disease Management | 1 | 2021 | 521 | 0.140 |
Why?
|
| Antipsychotic Agents | 2 | 2011 | 373 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 269 | 0.140 |
Why?
|
| Neurologists | 1 | 2017 | 17 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 479 | 0.140 |
Why?
|
| Algorithms | 3 | 2020 | 1616 | 0.140 |
Why?
|
| Disease Progression | 1 | 2023 | 2053 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 359 | 0.130 |
Why?
|
| Psychotropic Drugs | 1 | 2017 | 124 | 0.130 |
Why?
|
| Astrocytes | 1 | 2019 | 249 | 0.130 |
Why?
|
| Interinstitutional Relations | 1 | 2016 | 20 | 0.130 |
Why?
|
| Cyclophosphamide | 3 | 2016 | 421 | 0.130 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2016 | 35 | 0.130 |
Why?
|
| Adolescent Health Services | 1 | 2016 | 36 | 0.130 |
Why?
|
| Health Surveys | 1 | 2017 | 244 | 0.130 |
Why?
|
| Adolescent Behavior | 1 | 2017 | 168 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 154 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 230 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 585 | 0.120 |
Why?
|
| Basement Membrane | 1 | 2015 | 46 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 537 | 0.120 |
Why?
|
| Churg-Strauss Syndrome | 2 | 2012 | 21 | 0.120 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 60 | 0.120 |
Why?
|
| Weight Gain | 2 | 2022 | 405 | 0.120 |
Why?
|
| Injections, Spinal | 2 | 2025 | 121 | 0.120 |
Why?
|
| Vasculitis | 2 | 2012 | 50 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 232 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2024 | 824 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2025 | 12333 | 0.110 |
Why?
|
| Glomerulonephritis | 2 | 2011 | 73 | 0.110 |
Why?
|
| Quality of Life | 2 | 2025 | 1945 | 0.110 |
Why?
|
| Prevalence | 2 | 2010 | 2451 | 0.100 |
Why?
|
| Dyskinesias | 1 | 2013 | 19 | 0.100 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2012 | 20 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1265 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 138 | 0.100 |
Why?
|
| Young Adult | 5 | 2024 | 8981 | 0.100 |
Why?
|
| Cognition | 1 | 2017 | 731 | 0.100 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2012 | 21 | 0.100 |
Why?
|
| Physicians | 2 | 2016 | 582 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 558 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 142 | 0.090 |
Why?
|
| Aripiprazole | 1 | 2011 | 20 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 2901 | 0.090 |
Why?
|
| Risk Factors | 5 | 2018 | 10271 | 0.090 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 9 | 0.090 |
Why?
|
| Rheumatologists | 2 | 2022 | 9 | 0.090 |
Why?
|
| ADAMTS13 Protein | 1 | 2011 | 62 | 0.090 |
Why?
|
| Age of Onset | 3 | 2017 | 581 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 481 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5153 | 0.090 |
Why?
|
| Consensus | 3 | 2021 | 634 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1354 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 125 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2013 | 222 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2011 | 173 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 828 | 0.080 |
Why?
|
| Atrophy | 1 | 2010 | 236 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 506 | 0.080 |
Why?
|
| Immune System Diseases | 2 | 2021 | 46 | 0.080 |
Why?
|
| Executive Function | 1 | 2009 | 105 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 881 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 712 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 124 | 0.080 |
Why?
|
| Registries | 2 | 2012 | 1421 | 0.080 |
Why?
|
| Aftercare | 2 | 2022 | 148 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2011 | 230 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2025 | 1163 | 0.070 |
Why?
|
| Age Factors | 2 | 2012 | 2817 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1327 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2010 | 539 | 0.070 |
Why?
|
| Warfarin | 1 | 2007 | 119 | 0.060 |
Why?
|
| Biomarkers | 1 | 2015 | 3063 | 0.060 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 427 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2009 | 689 | 0.060 |
Why?
|
| Seizures | 2 | 2023 | 879 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 164 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2090 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 5810 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 1105 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 37 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 632 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 2024 | 78 | 0.060 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 338 | 0.050 |
Why?
|
| Spin Labels | 1 | 2023 | 39 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2024 | 230 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2021 | 32 | 0.050 |
Why?
|
| Methotrexate | 2 | 2016 | 341 | 0.050 |
Why?
|
| Time Factors | 2 | 2022 | 6308 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.050 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 280 | 0.050 |
Why?
|
| Infectious Encephalitis | 1 | 2020 | 4 | 0.050 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 39 | 0.040 |
Why?
|
| Cannabidiol | 1 | 2021 | 22 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 295 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 117 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 317 | 0.040 |
Why?
|
| Diet, Ketogenic | 1 | 2021 | 26 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 210 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 243 | 0.040 |
Why?
|
| Immunization | 1 | 2021 | 307 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 503 | 0.040 |
Why?
|
| Reference Standards | 2 | 2010 | 238 | 0.040 |
Why?
|
| Data Collection | 1 | 2021 | 383 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2009 | 6136 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 1401 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 496 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 723 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 28 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 850 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 3434 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2020 | 160 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Lymphoma | 1 | 2021 | 323 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1252 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 67 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1351 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 236 | 0.030 |
Why?
|
| Azathioprine | 1 | 2016 | 54 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2016 | 29 | 0.030 |
Why?
|
| Hearing Disorders | 1 | 1996 | 27 | 0.030 |
Why?
|
| Dizziness | 1 | 1996 | 26 | 0.030 |
Why?
|
| Tinnitus | 1 | 1996 | 19 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2016 | 19 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2016 | 10 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 952 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 51 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 107 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1996 | 107 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 112 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 99 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 91 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2044 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2018 | 323 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1118 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2825 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 415 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 16 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 28 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 43 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 286 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 675 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 320 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 341 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 212 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 208 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 69 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 308 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 306 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 565 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 204 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 723 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 762 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 824 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 34190 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 277 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2424 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 549 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1810 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 776 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 26700 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2142 | 0.020 |
Why?
|
| Tremor | 1 | 2013 | 130 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1996 | 764 | 0.020 |
Why?
|
| Headache | 1 | 2011 | 108 | 0.020 |
Why?
|
| Mass Screening | 1 | 2016 | 785 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2016 | 855 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1781 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4607 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 4261 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3589 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2018 | 1177 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3287 | 0.020 |
Why?
|
| Aging | 1 | 2014 | 1189 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8181 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4430 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2879 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4357 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 17752 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 209 | 0.010 |
Why?
|